Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?

Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historically associated with bariatric surgery and potentially giving Lilly another major product after the success of Mounjaro. The company’s stock price has